Unlock instant, AI-driven research and patent intelligence for your innovation.

Carbonyl heterocyclic compound and application thereof

A technology of heterocycles and compounds, applied in the field of carbonyl heterocycles, can solve problems such as lack of therapeutic agents

Pending Publication Date: 2022-03-18
SHANGAI PHARMA GRP CO LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to overcome the lack of therapeutic agents based on lanthionine synthase C-like 2 in the prior art; and provide a carbonyl heterocyclic compound and its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carbonyl heterocyclic compound and application thereof
  • Carbonyl heterocyclic compound and application thereof
  • Carbonyl heterocyclic compound and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0292] Example 1: 6-(1H-benzo[d]imidazol-2-yl)-N-(3-(3-(3-(imidazo[1,2-a]pyridin-2-yl)benzene Formyl)-3-azabicyclo[3.1.0]hexane-6-yl)pyridineamide (L-1)

[0293]

[0294] One, the synthesis of 3-(imidazo[1,2-a]pyridin-2-yl)methyl benzoate

[0295]

[0296] At room temperature, 2-aminopyridine (1.6g, 17mmol), methyl 3-acetoformate (2.3g, 14mmol) and cuprous iodide (0.5g, 2.8mmol) were dissolved in 1,4-dioxane In 50 mL, the reaction solution was heated to reflux overnight, and monitored by LC-MS until the end of the reaction. After concentration under reduced pressure, 50 mL of water was added, extracted with ethyl acetate (50 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was subjected to column chromatography (eluent: petroleum ether / ethyl acetate =5 / 1) separated and purified to obtain a white solid (1.8g, 7.4mmol) with a yield of 52%. LC-MS: [M+1] + :253.09

[0297] ...

Embodiment 2

[0304] Example 2 6-(1H-benzo[d]imidazol-2-yl)-N-(3-(3-(3-(imidazo[1,2-a]pyridin-2-yl)benzyl Acyl)-3-azabicyclo[3.1.0]hexan-6-yl)pyridineamide (L-2)

[0305]

[0306] Under ice bath, mix 3-(imidazo[1,2-a]pyridin-2-yl)benzoic acid (0.12g, 0.5mmol), 1-(3-dimethylaminopropyl)-3-ethyl carbon Diimine hydrochloride (0.1g, 0.52mmol), 1-hydroxybenzotriazole (0.07g, 0.52mmol) and N, N-diisopropylethylamine (0.14g, 1.13mmol) were dissolved in N, In N-dimethylformamide 6mL, after stirring for 0.5h, add 6-(1H-benzo[d]imidazol-2-yl)-N-(3-azabicyclo[3.1.0]hexane-6- Base) pyridine amide (0.16g, 0.5mmol), continue to stir for 0.5 hours and return to room temperature to react overnight. The reaction solution was poured into 20 mL of water, extracted with ethyl acetate (20 mL x 3), washed with saturated brine, combined with organic phases, dried over anhydrous sodium sulfate, and concentrated under reduced pressure by silica gel column chromatography (DCM:MeOH=20:1) to obtain Off-white sol...

Embodiment 3

[0308] Example 3: (9-(3-(1h-benzo[d]imidazol-2-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)(3 -(Imidazol[1,2-a]pyridin-2-yl)phenyl)methanone (L-3)

[0309]

[0310] Under ice bath, mix 3-(imidazo[1,2-a]pyridin-2-yl)benzoic acid (0.12g, 0.5mmol), 1-(3-dimethylaminopropyl)-3-ethyl carbon Diimine hydrochloride (0.1g, 0.52mmol), 1-hydroxybenzotriazole (0.07g, 0.52mmol) and N, N-diisopropylethylamine (0.14g, 1.13mmol) were dissolved in N, In N-dimethylformamide 6mL, after stirring for 0.5h, add 6-(1H-benzo[d]imidazol-2-yl)-N-(3-azabicyclo[3.1.0]hexane-6- Base) pyridine amide (0.18g, 0.5mmol), continued to stir for 0.5 hours and returned to room temperature to react overnight. The reaction solution was poured into 20 mL of water, extracted with ethyl acetate (20 mL x 3), washed with saturated brine, combined with organic phases, dried over anhydrous sodium sulfate, and concentrated under reduced pressure by silica gel column chromatography (DCM:MeOH=20:1) to obtain Off-white ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a carbonyl heterocyclic compound and application thereof. The invention provides a carbonyl heterocyclic compound as shown in a formula II or a pharmaceutically acceptable salt thereof. The compound can be used as a compound with a path of targeting the lantidine synthetase C-like protein 2; the compounds may be used to treat a variety of conditions, including infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases.

Description

technical field [0001] The invention relates to a carbonyl heterocyclic compound and its application. Background technique [0002] Lanthionine C-like protein 2 (LANCL2) (also known as "lanthionine synthase C-like protein 2" or "lanthionine synthase component C-like protein 2" is a protein expressed by immune cells, gastrointestinal Signaling pathway protein of the tract, neurons, testis and pancreas. Activation of the LANCL2 pathway increases insulin sensitivity and reduces inflammation associated with various autoimmune, inflammatory and metabolic pathologies. Results of in vivo and in vitro tests in mice demonstrated that use of compounds targeting this pathway reduced glucose levels 2-fold in glucose tolerance tests compared to controls and provided (GlaxoSmithKline plc, Brentford, England), is an effective treatment but has significant side effects. Targeting the LANCL2 pathway also reduced gut inflammation by 90%, with a corresponding 4-fold reduction in the number ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D519/00C07D471/04C07D401/14C07D239/42C07D471/10C07D401/04C07D409/14A61P37/02A61P29/00A61P3/00A61P31/00A61P3/10A61P31/16A61P1/00A61P1/04A61K31/437A61K31/496A61K31/4545A61K31/506A61K31/4439A61K31/407A61K31/444A61K31/5377
CPCC07D519/00C07D471/04C07D401/14C07D239/42C07D471/10C07D401/04C07D409/14A61P37/02A61P29/00A61P3/00A61P31/00A61P3/10A61P31/16A61P1/00A61P1/04A61K31/407A61K31/4439A61K31/444A61K31/437A61K31/4545A61K31/496A61K31/5377A61K31/506A61K31/4184A61K31/44A61P31/12C07D235/18C07D403/14C07D413/14
Inventor 张朝欣夏广新向志军柯樱楼江松赵蒙浩郝利军
Owner SHANGAI PHARMA GRP CO LTD